FFA
SRPT icon

Farther Finance Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Farther Finance Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$20.2K Sell
1,107
-1,221
-52% -$22.8K ﹤0.01% 4129
2026
Q2 		$41.7K Sell
2,328
-1,590
-41% -$30.1K ﹤0.01% 3389
2026
Q1 		$86.7K Sell
3,918
-2,251
-36% -$43.6K ﹤0.01% 2609
2025
Q4 		$133K Buy
6,169
+6,042
+4,757% +$127K ﹤0.01% 2169
2025
Q3 		$2.45K Buy
127
+22
+21% +$392 ﹤0.01% 4066
2025
Q2 		$1.8K Buy
105
+20
+24% +$853 ﹤0.01% 3737
2025
Q1 		$5.26K Sell
85
-219
-72% -$23.1K ﹤0.01% 3034
2024
Q4 		$37K Buy
304
+2
+0.7% +$245 ﹤0.01% 1806
2024
Q3 		$37.7K Buy
302
+12
+4% +$1.66K ﹤0.01% 1792
2024
Q2 		$45.5K Buy
290
+222
+326% +$28.5K ﹤0.01% 1457
2024
Q1 		$8.73K Buy
68
+3
+5% +$367 ﹤0.01% 1816
2023
Q4 		$6.27K Buy
65
+43
+195% +$4.13K ﹤0.01% 1848
2023
Q3 		$2.67K Buy
22
+3
+16% +$339 ﹤0.01% 1747
2023
Q2 		$2.18K Hold
19
– – ﹤0.01% 1723
2023
Q1 		$2.62K Hold
19
– – ﹤0.01% 1542
2022
Q4 		$2.46K Buy
+19
New +$2.2K ﹤0.01% 1383

Other funds holding SRPT

GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.95B AUM 16% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
MAFA
MJT & Associates Financial Advisory Monteviceo, Minnesota $155M AUM 15.7% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $148M AUM 25.13% 1-Year Est. Return
DCM
Davis Capital Management Jacksonville, Florida $167M AUM 17.17% 1-Year Est. Return

Farther Finance Advisors's SRPT Position: Q3 2026 in Review

Farther Finance Advisors reduced its Sarepta Therapeutics (SRPT) stake by 52% in Q3 2026, selling an estimated $22.8K and leaving 1,107 shares worth $20.2K. The position accounts for ﹤0.01% of the portfolio, ranked #4129.

Farther Finance Advisors first reported a position in SRPT in Q4 2022 and has held it in 16 quarters since. The position peaked at $133K in Q4 2025. 9 funds tracked by Wall St. Rank hold SRPT as of Q3 2026.

  • Farther Finance Advisors held 1,107 shares of Sarepta Therapeutics worth $20.2K as of Q3 2026.
  • Farther Finance Advisors sold 1,221 Sarepta Therapeutics shares in Q3 2026, an estimated $22.8K.
  • Sarepta Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #4129 holding.
  • Farther Finance Advisors first reported a position in Sarepta Therapeutics in Q4 2022 and has held it in 16 quarters since.
  • Farther Finance Advisors's Sarepta Therapeutics position peaked at $133K in Q4 2025.
  • 9 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.